Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Kerry A Casey, Xiang Guo, Michael A Smith, Shiliang Wang, Dominic Sinibaldi, Miguel A Sanjuan, Liangwei Wang, Gabor G Illei, Wendy I White, Kerry A Casey, Xiang Guo, Michael A Smith, Shiliang Wang, Dominic Sinibaldi, Miguel A Sanjuan, Liangwei Wang, Gabor G Illei, Wendy I White
Abstract
Objective: Anifrolumab is a fully human immunoglobulin G1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. Here, we evaluated serum proteins and immune cells associated with SLE pathogenesis, type I interferon gene signature (IFNGS) test status and disease activity, and how anifrolumab affected these components.
Methods: Whole blood samples were collected from patients enrolled in MUSE (NCT01438489) for serum protein and cellular assessments at baseline and subsequent time points. Data were parsed by IFNGS test status (high/low) and disease activity. Protein expression and immune cell subsets were measured using multiplex immunoassay and flow cytometry, respectively. Blood samples from healthy donors were analysed for comparison.
Results: Baseline protein expression differed between patients with SLE and healthy donors, IFNGS test-high and -low patients, and patients with moderate and severe disease. Anifrolumab treatment lowered concentrations of IFN-induced chemokines associated with B, T and other immune cell migration in addition to proteins associated with endothelial activation that were dysregulated at baseline. IFNGS test-high patients and those with high disease activity were characterised by low baseline numbers of lymphocytes, circulating memory T-cell subsets and neutrophils. Anifrolumab treatment reversed lymphopenia and neutropenia in the total population, and normalised multiple T-cell subset counts in IFNGS test-high patients compared with placebo.
Conclusions: Anifrolumab treatment reversed IFN-associated changes at the protein and cellular level, indicating multiple modes of activity.
Trial registration number: NCT01438489.
Keywords: disease activity; monoclonal antibody; systemic lupus erythematosus; type I interferon.
Conflict of interest statement
Competing interests: KAC, XG, MAS, SW, DS and WW are employees of MedImmune and hold stock and/or stock options in AstraZeneca. MAS was an employee of MedImmune at the time that this analysis was conducted; he is now an employee of Bristol-Myers Squibb. LW was an employee of MedImmune at the time that this analysis was conducted; he is now an employee of AstraZeneca. GI was an employee of MedImmune at the time that this analysis was conducted; he is now an employee of Viela Bio.
Figures
References
- Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 2018;30:144–50. 10.1097/BOR.0000000000000480
- Petri M, Purvey S, Fang H, et al. . Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021–8. 10.1002/art.34672
- Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30. 10.1002/art.30613
- Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017;13:799–814. 10.1080/1744666X.2017.1327352
- Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676–82. 10.1016/j.coi.2006.09.014
- Crow MK, Olferiev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296–305. 10.1016/j.trsl.2014.10.005
- Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011;23:113–21. 10.1016/j.smim.2011.01.009
- Spadaro F, Lapenta C, Donati S, et al. . IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012;119:1407–17. 10.1182/blood-2011-06-363564
- Simmons DP, Wearsch PA, Canaday DH, et al. . Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J Immunol 2012;188:3116–26. 10.4049/jimmunol.1101313
- Eloranta ML, Rönnblom L. Cause and consequences of the activated type I interferon system in SLE. J Mol Med 2016;94:1103–10. 10.1007/s00109-016-1421-4
- Knight JS, Kaplan MJ. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr Opin Rheumatol 2012;24:441–50. 10.1097/BOR.0b013e3283546703
- Garcia-Romo GS, Caielli S, Vega B, et al. . Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:ra20 10.1126/scitranslmed.3001201
- Baechler EC, Batliwalla FM, Karypis G, et al. . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610–5. 10.1073/pnas.0337679100
- Bennett L, Palucka AK, Arce E, et al. . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–23. 10.1084/jem.20021553
- Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481–90. 10.1080/08916930310001625952
- Han GM, Chen SL, Shen N, et al. . Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177–86. 10.1038/sj.gene.6363966
- Peng L, Oganesyan V, Wu H, et al. . Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs 2015;7:428–39. 10.1080/19420862.2015.1007810
- Riggs JM, Hanna RN, Rajan B, et al. . Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med 2018;5:e000261.
- Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376–86. 10.1002/art.39962
- Henault J, Riggs JM, Karnell JL, et al. . Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat Immunol 2016;17:196–203. 10.1038/ni.3326
- O'Hara DM, Xu Y, Liang Z, et al. . Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 2011;363:120–34. 10.1016/j.jim.2010.09.036
- Bauer JW, Baechler EC, Petri M, et al. . Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491 10.1371/journal.pmed.0030491
- Nakagawa M, Terashima T, D'yachkova Y, et al. . Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998;98:2307–13. 10.1126/science.280.5362.450
- Shoenfeld Y, Gurewich Y, Gallant LA, et al. . Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis. Am J Med 1981;71:773–8.
- Bengtsson AA, Sturfelt G, Truedsson L, et al. . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664–71. 10.1191/096120300674499064
- Suwantarat N, Tice AD, Khawcharoenporn T, et al. . Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci 2010;7:36–42.
- Rönnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003;5:68–75. 10.1186/ar625
- Lub-de Hooge MN, de Vries EG, de Jong S, et al. . Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854–8. 10.1136/ard.2004.029058
- Havenar-Daughton C, Lindqvist M, Heit A, et al. . CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A 2016;113:2702–7. 10.1073/pnas.1520112113
- Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur J Immunol 2016;46:281–90. 10.1002/eji.201545760
- Tanaka A, Tsukamoto H, Mitoma H, et al. . Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther 2012;14:R244 10.1186/ar4087
- Bauer JW, Petri M, Batliwalla FM, et al. . Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098–107. 10.1002/art.24803
- Jacobi AM, Huang W, Wang T, et al. . Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010;62:201–10. 10.1002/art.27189
- Anolik JH, Barnard J, Cappione A, et al. . Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580–90. 10.1002/art.20592
- Guo X, Higgs BW, Bay-Jensen AC, et al. . Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 2015;135:2402–9. 10.1038/jid.2015.188
- Guo X, Higgs BW, Rebelatto M, et al. . Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology 2014;53:686–95. 10.1093/rheumatology/ket413
Source: PubMed